FDA Concerned About Cancer Risks of Hypertension Drugs
Published by Brenda Fulmer in Defective Design, Mass Torts, Product DefectThe FDA announced yesterday, July 15, 2010, that a class of drugs known as ARBs (Angiotensin-receptor blockers) is being reviewed after a recent study found an increased risk of cancer associated with their use.
ARBs (Angiotensin-receptor blockers) are regularly prescribed for the treatment of hypertension (high blood pressure), diabetic nephropathy (kidney damage due to Diabetes) and congestive heart failure. Some of the more common brand names of ARBs include Diovan (valsartan), Cozaar (losartan), Avapro (irbesartan), Benicar (olmesartan) and Micardis (telmisartan).
The study cited by the FDA was conducted by a team of researchers, led by Dr. Ilke Sipahi, from the University Hospitals Case Western Medical Center in Cleveland. The team synthesized newly available data from other large scale clinical trials to look for a correlation between cancer development and the use of these drugs. The study concluded that “patients randomly assigned to receive ARBs had a significantly increased risk of new cancer occurrence compared with patients in control groups… Among specific solid organ cancers examined, only new lung-cancer occurrence was significantly higher…”[1] showing the possible cancer risk that could follow the use of this class of drugs.
The FDA plans to continue their review of these studies to determine additional information about any increased risks associated with the use of these medications. They will release any additional information to the public as it becomes available. At this time, they recommend that healthcare professionals and their patients continue to use these medications as their respective labels advise, but caution the community to stay alert to the possibility of the associated risks. It is important that anyone using these medications continue with their use unless otherwise advised by their physician.
Healthcare professionals or patients taking these medications are encouraged to any report adverse events or side effects related to their use to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program.
Tags: Angiotensin-receptor blockers, ARBs, cancer development, cancer risk, FDA, hypertension, safety, treatment of hypertension
November 4th, 2011 at 10:41 am
very direct
November 4th, 2011 at 5:34 pm
thanks ok
November 8th, 2011 at 6:05 am
Woah! I’m really digging the template/theme of this blog. It’s simple, yet effective. A lot of times it’s very hard to get that “perfect balance” between superb usability and visual appearance. I must say that you’ve done a awesome job with this. Also, the blog loads very quick for me on Firefox. Superb Blog!
November 8th, 2011 at 5:57 pm
Gaga has (blank) in recent months made an appearance at Europride, held in Rome in June 2011
November 9th, 2011 at 2:11 am
good info
November 10th, 2011 at 1:24 pm
nice post
November 19th, 2011 at 12:19 pm
Hello.This article was extremely remarkable, particularly since I was searching for thoughts on this issue last couple of days.
November 26th, 2011 at 2:10 am
This article gives the light in which we are able to observe the reality. This can be exceptionally great 1 and provides in-depth information.
December 2nd, 2011 at 8:29 pm
strongzz Valuable information. Lucky me I found your site by accident, and I’m shocked why this accident did not happened earlier! I bookmarked it.
December 17th, 2011 at 4:27 pm
strongzz Heya i’m for the first time here. I came across this board and I find It really useful & it helped me out a lot. I hope to give something back and aid others like you aided me.
January 4th, 2012 at 3:29 pm
If you’re still on the fence: grab your favorite earphones, head down to a Best Buy and ask to plug them into a Zune then an iPod and see which one sounds better to you, and which interface makes you smile more. Then you’ll know which is right for you.
February 7th, 2012 at 4:35 am
Cześć. To było ciekawe. Pozdrawiam